Avita Medical share price tumbles 7% on declining Q1 revenue

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

The Avita Medical Inc (ASX: AVH) share price is down 7.2% to $1.62 in early trade.

Avita focuses on regenerative medicines. Its spray-on Recell medicine is used to treat burn patients.

Below we look at the ASX healthcare share’s first-quarter results for the three months ending 31 March (Q1 2022).

What was reported for the quarter?

The Avita Medical share price is sliding after the company a 14% decrease in revenue compared to Q1 2021. Revenue for the quarter came in at $7.5 million.

The company reported the decline was largely due to its recognition of $4.1 million in Biomedical Advanced Research and Development Authority (BARDA) related revenue in 2021.

Avita’s Q1 2022 commercial revenue increased 61% year-on-year to $2.8 million. It attributed the lift to “broader utilisation among our customer base as well as deeper penetration within individual customer accounts”.

Gross profits of $5.7 million were down 13% from the $6.6 million reported in the prior corresponding period. Gross profit margin of 76% was identical to Q1 2021.

Operating expenses increased $2.8 million to $16.0 million, 21% higher than the corresponding quarter.

On the bottom line, and likely pressuring the Avita Medical share price today, the company reported a net loss of $9.5 million. That’s 58% more than the $6.0 million net loss reported for the first three months of 2021.

What’s next?

The company intends to use its cash reserves until US sales of its products ramp up to levels where those revenues can fund its ongoing operations. As at 31 March, Avita reported it has enough cash reserves to fund operations for the next 12 months.

Avita added, “We have no committed plans to issue further shares on the market.”

As for dividends?

“There were no dividends paid and we have no plans to commence the payment of dividends.”

Avita Medical share price snapshot

With this morning’s intraday losses factored in, the Avita Medical share price is down a painful 53% in 2022. That compares to a year-to-date loss of 9% posted by the All Ordinaries Index (ASX: XAO).

The post Avita Medical share price tumbles 7% on declining Q1 revenue appeared first on The Motley Fool Australia.

Should you invest $1,000 in Avita Medical right now?

Before you consider Avita Medical, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Avita Medical wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/CoQlmkA

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s